Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
What dose contraints do use for the pulmonary artery and vein when treating with a lung lesion with SBRT?
Related Questions
What is your preferred approach for managing oligoprogressive NSCLC during second-line or later systemic therapy if patient is otherwise responding well at other sites of disease?
How would you manage out-of-field nodal recurrence of NSCLC post definitive CRT and adjuvant immunotherapy?
Is moderately hypofractionated RT using 60 Gy/20fx with concurrent chemotherapy appropriate for unresectable stage III NSCLC?
What CTV expansions do you use for NSCLC with conventional chemoradiation and do you do different expansions based on specific histologies?
How do you manage a cytology-negative pleural effusion that develops after lung RT?
How are you incorporating Tumor Treating Fields for locally progressive/metastatic NSCLC, if at all?
How would you treat a patient with newly diagnosed ALK+ Stage IIIB non-small cell lung cancer (NSCLC)?
What systemic therapy would you offer to a patient with metastatic EGFR exon 19 deleted NSCLC to the brain with isolated CNS progression while on osimertinib 80 mg and progressed through WBRT?
What is your approach to adjuvant RT or chemoRT in LS-SCLC s/p lobectomy with N1 disease?
How do you construct your target volumes for superior sulcus tumors?
